Leadership & Pay ·
BetterLife Pharma Inc. appointed Dr. Mahan Chehrenama, DO, as Chief Medical Officer to lead clinical development for…
BETRFBetterLife Pharma Inc.
BetterLife Pharma Inc. appointed Dr. Mahan Chehrenama, DO, as Chief Medical Officer to lead clinical development for BETR-001, a non-hallucinogenic neuroplastogen targeting migraine and headache disorders, with an Investigational New Drug application anticipated in the first quarter of 2027. The company granted Dr. Chehrenama stock options to purchase 500,000 common shares at an exercise price of $0.285, vesting quarterly over 24 months. Additionally, from August 1 to 21, 2026, the company received gross proceeds of $531,470 from the exercise of 4,564,697 share purchase warrants issued at prices between $0.10 and $0.15. The company also rescheduled its 2026 annual general meeting to October 14, 2026, and adopted new governance committee charters. BetterLife Pharma Inc. is a biotechnology company developing treatments for neurological disorders.